An AI decision aid significantly improved decision quality, level of shared decision-making, patient satisfaction and functional outcomes in patients compared to an education-only approach, according to a new study in JAMA.
This latest analysis is an extension of the COAPT trial, which had examined the safety and effectiveness of TMVR with the MitraClip device after two years.
The reported exploration to sell Watson Health, the AI-driven health business of IBM, underscores deep challenges with technology in solving healthcare problems, according to the Wall Street Journal.